---
agent: Compliance Officer
company: Meridian Health Partners
task: Vendor BAA Review
generated: 2026-02-17T04:00:00Z
model: claude-sonnet-4-20250514
---

# Vendor BAA Compliance Review â€” February 2026

**Review Date:** February 17, 2026
**Review Type:** Monthly Follow-up Audit
**Conducted By:** Compliance Officer Agent
**Previous Review:** February 16, 2026

---

## Executive Summary

Follow-up review of **15 active vendor BAAs** following critical findings from the February 16 audit. **LabCorp renewal remains unexecuted** â€” escalation triggered. Quest Diagnostics renewal is progressing on schedule. Additionally identified **1 new concern**: PharmaCorp BAA contains outdated breach notification language that does not meet the 2025 HIPAA Final Rule requirements.

| Status | Count | Change vs. Feb 16 |
|---|---|---|
| âœ… Compliant & Current | 11 | -1 |
| ğŸ”´ Expired / Non-Compliant | 2 | +1 |
| ğŸŸ¡ Expiring Within 30 Days | 1 | â€” |
| ğŸ”µ Pending Renewal | 1 | â€” |
| **Total Vendors** | **15** | â€” |

---

## Critical Updates Since Last Review

### ğŸ”´ EXPIRED â€” LabCorp Diagnostics (ESCALATED)

- **BAA Status:** Expired since January 31, 2026 â€” now **17 days overdue**
- **Agreement ID:** BAA-2024-LC-0087
- **Update:** LabCorp legal returned redlined draft on Feb 15 with 4 substantive changes to indemnification and breach notification clauses. Our legal team counter-proposed on Feb 16. Awaiting LabCorp response.
- **PHI Exposure:** 312 lab orders processed since expiration without valid BAA
- **Risk Level:** ğŸ”´ **Critical** â€” Continued operation without BAA constitutes willful HIPAA violation
- **Recommended Action:** If not executed by Feb 21, suspend all PHI transmissions to LabCorp and reroute to Quest Diagnostics (pending their renewal) or backup vendor MedLab Direct
- **Escalated To:** Chief Compliance Officer Margaret Wu, General Counsel David Park

### ğŸ”´ NEW FINDING â€” PharmaCorp Rx (Non-Compliant Language)

- **BAA Status:** Active (expires Sep 30, 2026) but **non-compliant with 2025 HIPAA Final Rule**
- **Agreement ID:** BAA-2025-PC-0203
- **Issue:** Section 7.2 (Breach Notification) requires notification within 60 days. The 2025 HIPAA Final Rule (effective Jan 1, 2026) reduced the maximum notification window to **30 days** for breaches affecting 500+ individuals.
- **Impact:** PharmaCorp processes prescription data for ~4,200 patients. A breach affecting this population under the current BAA language would leave Meridian non-compliant with federal notification requirements.
- **Risk Level:** ğŸ”´ **High** â€” Amendment required
- **Recommended Action:** Issue BAA amendment to update Section 7.2 to 30-day notification window. Template amendment drafted and attached for legal review.

### ğŸŸ¡ ON TRACK â€” Quest Diagnostics

- **BAA Status:** Expiring February 28, 2026 â€” **11 days remaining**
- **Agreement ID:** BAA-2024-QD-0112
- **Update:** Legal review completed Feb 16. Clean draft sent to Quest for countersignature. Expected execution by Feb 21.
- **Risk Level:** ğŸŸ¡ Medium â€” On track but monitoring daily

---

## Amended BAA Template â€” PharmaCorp Section 7.2

**Current Language:**
> Business Associate shall report any Breach of Unsecured PHI to Covered Entity without unreasonable delay and in no case later than sixty (60) calendar days after discovery of the Breach.

**Proposed Amendment:**
> Business Associate shall report any Breach of Unsecured PHI to Covered Entity without unreasonable delay and in no case later than **thirty (30) calendar days** after discovery of the Breach, in accordance with 45 CFR Â§164.410 as amended by the 2025 HIPAA Final Rule. For Breaches affecting 500 or more individuals, Business Associate shall provide Covered Entity with sufficient information to enable Covered Entity to comply with the 30-day individual notification requirement under Â§164.404(b).

---

## Compliance Scorecard

| Vendor | BAA Current | Breach Notification Compliant | Subcontractor Flow-Down | Annual Review Complete |
|---|---|---|---|---|
| LabCorp Diagnostics | âŒ | N/A | N/A | âŒ |
| Quest Diagnostics | ğŸŸ¡ | âœ… | âœ… | âœ… |
| SecureShred LLC | ğŸ”µ | âœ… | âœ… | ğŸ”µ |
| CloudMedix EHR | âœ… | âœ… | âœ… | âœ… |
| PharmaCorp Rx | âœ… | âŒ | âœ… | âœ… |
| MedTranscribe Pro | âœ… | âœ… | âœ… | âœ… |
| BioWaste Mgmt Inc | âœ… | âœ… | âœ… | âœ… |
| Pacific Billing Co | âœ… | âœ… | âœ… | âœ… |
| HealthBridge IT | âœ… | âœ… | âœ… | âœ… |
| Apex Imaging Solutions | âœ… | âœ… | âœ… | âœ… |
| ClearView Analytics | âœ… | âœ… | âœ… | âœ… |
| NurseLine Connect | âœ… | âœ… | âœ… | âœ… |
| DocuSign Health | âœ… | âœ… | N/A | âœ… |
| Pinnacle Staffing | âœ… | âœ… | âœ… | âœ… |
| SafeComm Telehealth | âœ… | âœ… | âœ… | âœ… |

---

## Action Items

| Priority | Action | Owner | Deadline |
|---|---|---|---|
| ğŸ”´ Critical | Execute LabCorp BAA or suspend PHI sharing | Legal / CCO Wu | Feb 21, 2026 |
| ğŸ”´ High | Send PharmaCorp BAA amendment (Sec 7.2) | Compliance Officer Agent | Feb 18, 2026 |
| ğŸŸ¡ Medium | Confirm Quest Diagnostics countersignature | Legal | Feb 24, 2026 |
| ğŸ”µ Routine | Send SecureShred renewal package | Compliance | Mar 15, 2026 |
| ğŸ“‹ Monitoring | Daily check on LabCorp negotiation status | Compliance Officer Agent | Ongoing |

---

*Generated by Compliance Officer Agent â€¢ Meridian Health Partners â€¢ claude-sonnet-4-20250514*
